[go: up one dir, main page]

DK3122752T3 - 4'-substituerede nukleosidderivater som hiv-reverse transskriptasehæmmere - Google Patents

4'-substituerede nukleosidderivater som hiv-reverse transskriptasehæmmere Download PDF

Info

Publication number
DK3122752T3
DK3122752T3 DK15715934.4T DK15715934T DK3122752T3 DK 3122752 T3 DK3122752 T3 DK 3122752T3 DK 15715934 T DK15715934 T DK 15715934T DK 3122752 T3 DK3122752 T3 DK 3122752T3
Authority
DK
Denmark
Prior art keywords
reverse transcriptase
transcriptase inhibitors
hiv reverse
substituted nucleoside
nucleoside derivatives
Prior art date
Application number
DK15715934.4T
Other languages
English (en)
Inventor
Vinay M Girijavallabhan
David B Olsen
Zhibo Zhang
Jianmin Fu
Bing-Yu Tang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52824598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3122752(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of DK3122752T3 publication Critical patent/DK3122752T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15715934.4T 2014-03-28 2015-03-26 4'-substituerede nukleosidderivater som hiv-reverse transskriptasehæmmere DK3122752T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2014/074294 WO2015143712A1 (en) 2014-03-28 2014-03-28 4'-substituted nucleoside reverse transcriptase inhibitors
PCT/US2015/022621 WO2015148746A1 (en) 2014-03-28 2015-03-26 4'-substituted nucleoside-derivatives as hiv reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
DK3122752T3 true DK3122752T3 (da) 2021-10-25

Family

ID=52824598

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15715934.4T DK3122752T3 (da) 2014-03-28 2015-03-26 4'-substituerede nukleosidderivater som hiv-reverse transskriptasehæmmere

Country Status (42)

Country Link
US (2) US9777035B2 (da)
EP (1) EP3122752B1 (da)
JP (1) JP6182680B2 (da)
KR (1) KR101961009B1 (da)
CN (1) CN106795199B (da)
AP (1) AP2016009482A0 (da)
AR (2) AR099788A1 (da)
AU (2) AU2015236018B2 (da)
CA (1) CA2943792C (da)
CL (1) CL2016002414A1 (da)
CR (1) CR20160451A (da)
CY (1) CY1124829T1 (da)
DK (1) DK3122752T3 (da)
DO (1) DOP2016000265A (da)
EA (1) EA031476B1 (da)
EC (1) ECSP16085206A (da)
ES (1) ES2894228T3 (da)
GE (1) GEP20197009B (da)
GT (1) GT201600201A (da)
HR (1) HRP20211622T1 (da)
HU (1) HUE056913T2 (da)
IL (1) IL247923B (da)
JO (1) JO3636B1 (da)
LT (1) LT3122752T (da)
MA (1) MA39809B1 (da)
MD (1) MD4812C1 (da)
MX (1) MX367058B (da)
MY (1) MY194635A (da)
NI (1) NI201600145A (da)
NZ (1) NZ724343A (da)
PE (1) PE20170197A1 (da)
PH (1) PH12016501897B1 (da)
PL (1) PL3122752T3 (da)
PT (1) PT3122752T (da)
RS (1) RS62418B1 (da)
SG (1) SG11201608031PA (da)
SI (1) SI3122752T1 (da)
SV (1) SV2016005290A (da)
TW (1) TWI660967B (da)
UA (1) UA120758C2 (da)
WO (2) WO2015143712A1 (da)
ZA (1) ZA201606413B (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41213A (fr) * 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
CA2995365C (en) 2015-08-13 2021-10-12 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
WO2017053216A2 (en) * 2015-09-23 2017-03-30 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
JOP20170038B1 (ar) 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
US10138248B2 (en) 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
CR20190168A (es) 2016-10-04 2019-05-17 Merck Sharp & Dohme Compuestos de benzo[b]tiofeno como agonistas de sting
JP7125714B2 (ja) * 2016-12-13 2022-08-25 ヤマサ醤油株式会社 抗ウイルス活性を有する２’－デオキシ－７－デアザプリンヌクレオシド誘導体
WO2018208667A1 (en) 2017-05-12 2018-11-15 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
MA49772A (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Agonistes benzo[b]thiophène de sting pour le traitement du cancer
WO2019027857A1 (en) 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. COMBINATIONS OF PD-1 ANTAGONISTS AND STING BENZO [B] THIOPHENIC AGONISTS FOR THE TREATMENT OF CANCER
KR102696517B1 (ko) * 2017-09-18 2024-08-21 얀센 바이오파마, 인크. 치환된 뉴클레오시드, 뉴클레오티드 및 이들의 유사체
WO2019125974A1 (en) 2017-12-20 2019-06-27 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
CA3087192A1 (en) * 2017-12-27 2019-07-04 Raymond F. Schinazi Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents
US20200407393A1 (en) * 2018-03-07 2020-12-31 Glaxosmithkline Intellectual Property (No. 2) Limited Medical Use
CN111971277B (zh) 2018-04-03 2023-06-06 默沙东有限责任公司 作为sting激动剂的苯并噻吩及相关化合物
US11702430B2 (en) 2018-04-03 2023-07-18 Merck Sharp & Dohme Llc Aza-benzothiophene compounds as STING agonists
CA3105823C (en) 2018-07-09 2023-07-25 Merck Sharp & Dohme Corp. Enzymatic synthesis of 4'-ethynyl nucleoside analogs
US20220117993A1 (en) * 2018-08-09 2022-04-21 Glaxosmithkline Intellectual Property (No. 2) Limited Compounds Useful in HIV Therapy
AU2020211600A1 (en) 2019-01-25 2021-07-22 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
MA55200A (fr) 2019-03-06 2022-01-12 Glaxosmithkline Ip No 2 Ltd Composés utiles dans la thérapie du vih
CN110054654B (zh) * 2019-05-27 2022-12-27 武汉百科药物开发有限公司 一种地西他滨中间体α-取代脱氧核糖的合成方法
CN114502175B (zh) * 2019-07-27 2025-02-25 腾盛博药生物科技有限公司 腺苷衍生物和包含其的药物组合物
MX2022002899A (es) * 2019-09-11 2022-05-16 Scripps Research Inst Profarmacos antivirales y composiciones farmaceuticas de los mismos.
IL293566A (en) * 2019-12-09 2022-08-01 Viiv Healthcare Co Pharmaceutical preparations containing Cabotgravir
AR121356A1 (es) 2020-02-18 2022-05-11 Gilead Sciences Inc Compuestos antivirales
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
CN112321589B (zh) * 2020-02-18 2022-05-03 山东科巢生物制药有限公司 一种抗病毒药物瑞德西韦及其中间体的合成方法
TWI845826B (zh) 2020-03-20 2024-06-21 美商基利科學股份有限公司 4'-c-經取代-2-鹵基-2'-去氧腺苷核苷之前藥及其製造與使用方法
CN112778310B (zh) * 2020-04-20 2025-05-30 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN113527303B (zh) * 2020-04-21 2022-06-10 浙江工业大学 一种瑞德西韦母核中间体的制备工艺
CN113637041B (zh) * 2020-05-11 2024-02-27 上海科胜药物研发有限公司 一种核糖核苷的制备方法
PH12022553530A1 (en) 2020-06-24 2024-06-24 Gilead Sciences Inc 1'-cyano nucleoside analogs and uses thereof
MX2023001507A (es) 2020-08-07 2023-03-06 Gilead Sciences Inc Profarmacos de analogos de nucleotidos de fosfonamida y su uso farmaceutico.
ES2985995T3 (es) * 2020-08-27 2024-11-08 Gilead Sciences Inc Compuestos y métodos para el tratamiento de infecciones víricas
US20240101589A1 (en) 2020-10-08 2024-03-28 Strom Therapeutics Limited Inhibitors of mettl3
CN112300236A (zh) * 2020-10-21 2021-02-02 佛山科学技术学院 核苷酸混合氨基磷酸酯化合物、其药物组合物及其应用
WO2022159872A1 (en) * 2021-01-25 2022-07-28 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
AU2022211056A1 (en) 2021-01-25 2023-07-20 Brii Biosciences, Inc. Combination therapy for hiv with adenosine derivative and capsid inhibitors
EP4323362B1 (en) 2021-04-16 2025-05-07 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
CA3228162A1 (en) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
WO2023022216A1 (ja) 2021-08-20 2023-02-23 塩野義製薬株式会社 ウイルス増殖抑制作用を有するヌクレオシド誘導体及びそれらのプロドラッグ
US20250066365A1 (en) 2021-09-23 2025-02-27 Katholieke Universiteit Leuven Ribonucleoside Analogues Against -Sars-Cov-2
US20230295172A1 (en) 2022-03-02 2023-09-21 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
PE20250684A1 (es) 2022-03-15 2025-03-04 Rome Therapeutics Inc Compuestos y metodos para el tratamiento de enfermedades
EP4658663A2 (en) 2023-01-30 2025-12-10 Merck Sharp & Dohme LLC Prodrugs of 4'-substituted nucleoside reverse transcriptase inhibitors
WO2024226983A2 (en) * 2023-04-26 2024-10-31 Lakewood Amedex, Inc. Substituted pyrimidinone and azapyrimidinone compounds, compositions, and uses thereof
AR133187A1 (es) 2023-07-07 2025-09-03 Merck Sharp & Dohme Llc Derivados de tetrahidroquinazolina como agentes citotóxicos selectivos
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991010671A1 (en) 1990-01-11 1991-07-25 Isis Pharmaceuticals, Inc. Compositions and methods for detecting and modulating rna activity and gene expression
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
DE69729887T2 (de) 1996-10-16 2005-07-28 ICN Pharmaceuticals, Inc., Costa Mesa Purin-L-Nukleoside, Analoga und deren Verwendung
ES2207504T3 (es) 1999-05-12 2004-06-01 Yamasa Corporation Nucleosidos 4'-c-etinilpurina.
US6831069B2 (en) 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
US20040014957A1 (en) 2002-05-24 2004-01-22 Anne Eldrup Oligonucleotides having modified nucleoside units
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
WO2005003047A1 (en) 2003-07-03 2005-01-13 Philips Intellectual Property & Standards Gmbh Pane which can be heated by means of invisible light
CA2502109C (en) 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
CA2637879A1 (en) 2006-02-14 2007-08-23 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
CN101003550B (zh) * 2006-12-30 2010-05-19 河南省分析测试研究中心 8-卤代腺嘌呤类核苷化合物、合成方法和其药物用途
NZ598927A (en) 2007-01-12 2013-09-27 Biocryst Pharm Inc Antiviral nucleoside analogs
CN100532388C (zh) * 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
HUE025528T2 (en) 2008-04-23 2016-05-30 Gilead Sciences Inc 1'-substituted carba-nucleoside analogs for antiviral treatment
WO2010036407A2 (en) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
GB0815968D0 (en) 2008-09-03 2008-10-08 Angeletti P Ist Richerche Bio Antiviral agents
CN102216316A (zh) 2008-09-05 2011-10-12 寿制药株式会社 取代胺衍生物及以其为有效成分的药物组合物
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
DE102009000180A1 (de) 2009-01-13 2010-07-15 Evonik Degussa Gmbh Verfahren zur Herstellung von mehrschichtig beschichteten Gummipartikeln und mehrschichtig beschichtete Gummipartikel
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
EP2623104A1 (en) 2009-03-20 2013-08-07 Alios Biopharma, Inc. Substituted nucleoside and nucleotide analogs
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
US8551984B2 (en) 2009-12-17 2013-10-08 Merck Sharp & Dohme Corp. Aminopyrimidines as SYK inhibitors
EP2576561A1 (en) 2010-05-28 2013-04-10 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as janus kinase inhibitors
US20120027752A1 (en) 2010-07-22 2012-02-02 Gilead Sciences, Inc. Methods and compounds for treating paramyxoviridae virus infections
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
KR102068856B1 (ko) * 2012-03-13 2020-01-21 길리애드 사이언시즈, 인코포레이티드 항바이러스 치료를 위한 2'-치환된 카바-뉴클레오시드 유사체
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ

Also Published As

Publication number Publication date
HUE056913T2 (hu) 2022-03-28
MD20160117A2 (ro) 2017-02-28
WO2015148746A1 (en) 2015-10-01
UA120758C2 (uk) 2020-02-10
MD4812B1 (ro) 2022-06-30
HRP20211622T1 (hr) 2022-03-04
AU2015236018B2 (en) 2017-09-28
CN106795199A (zh) 2017-05-31
AR099788A1 (es) 2016-08-17
PE20170197A1 (es) 2017-03-22
CY1124829T1 (el) 2022-11-25
CL2016002414A1 (es) 2017-05-05
KR20160128437A (ko) 2016-11-07
US20180002366A1 (en) 2018-01-04
SG11201608031PA (en) 2016-10-28
PL3122752T3 (pl) 2022-01-03
LT3122752T (lt) 2021-11-10
WO2015143712A1 (en) 2015-10-01
CR20160451A (es) 2016-12-06
MA39809A (fr) 2021-04-07
TWI660967B (zh) 2019-06-01
AR130699A2 (es) 2025-01-08
MX367058B (es) 2019-08-02
CA2943792A1 (en) 2015-10-01
KR101961009B1 (ko) 2019-03-21
AP2016009482A0 (en) 2016-10-31
JP2017512797A (ja) 2017-05-25
US9777035B2 (en) 2017-10-03
EA201691931A1 (ru) 2017-02-28
AU2017225090B2 (en) 2018-08-09
BR112016022438A2 (pt) 2017-08-15
US20150274767A1 (en) 2015-10-01
PH12016501897A1 (en) 2016-12-19
CA2943792C (en) 2020-02-25
JO3636B1 (ar) 2020-08-27
ECSP16085206A (es) 2017-08-31
NZ724343A (en) 2020-02-28
CN106795199B (zh) 2020-01-10
PT3122752T (pt) 2021-10-20
IL247923B (en) 2021-01-31
PH12016501897B1 (en) 2023-08-02
DOP2016000265A (es) 2017-04-30
TW201619180A (zh) 2016-06-01
GEP20197009B (en) 2019-08-12
SI3122752T1 (sl) 2021-11-30
EP3122752A1 (en) 2017-02-01
BR112016022438A8 (pt) 2021-06-29
SV2016005290A (es) 2018-05-03
IL247923A0 (en) 2016-11-30
GT201600201A (es) 2018-12-18
MD4812C1 (ro) 2023-01-31
EA031476B1 (ru) 2019-01-31
MX2016012659A (es) 2016-12-14
NI201600145A (es) 2016-10-27
MA39809B1 (fr) 2021-10-29
AU2017225090A1 (en) 2017-09-28
RS62418B1 (sr) 2021-10-29
MY194635A (en) 2022-12-08
ZA201606413B (en) 2018-04-25
EP3122752B1 (en) 2021-08-25
JP6182680B2 (ja) 2017-08-16
ES2894228T3 (es) 2022-02-14
AU2015236018A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
DK3122752T3 (da) 4'-substituerede nukleosidderivater som hiv-reverse transskriptasehæmmere
DK3464249T3 (da) Substituerede carbonnukleosidderivater, der er anvendelige som anticancermidler
DK3302448T3 (da) Erstattede heterocyclylafledninger som cdk-inhibitore
DK3464271T3 (da) Pyrazolderivater som plasma-kallikreininhibitorer
ZA201705092B (en) Substituted nucleoside derivatives useful as anticancer agents
DK3204381T3 (da) N-pyridinylacetamidderivater som wnt-signaleringsbanehæmmere
LT3236972T (lt) Antivirusiniai n4-hidroksicitidino dariniai
DK3464309T3 (da) Phosphoramidatnukleosidderivater som anticancermidler
DK3149001T3 (da) Hidtil ukendte pyrazolopyrimidinderivater og deres anvendelse som MALT1-hæmmere
IL246929A0 (en) 4'-difluoromethyl-substituted nucleoside compounds as inhibitors of influenza RNA replication
DK3094631T3 (da) Pyrimidinyloxybenzenderivater som herbicider
DK3204378T6 (da) N-pyridinylacetamidderivater som hæmmere af wnt-signaleringsbanen
DK3313832T3 (da) 3-tetrazolyl-benzen-1,2-disulfonamidderivater som metallo-beta- lactamase-hæmmere
DK3601225T3 (da) Substituerede indolinderivater som inhibitorer af denguevirus-replikation
DK3310784T3 (da) Tricykliske forbindelser og deres anvendelse som phosphodiesterasehæmmere
DK3153508T3 (da) Naphthofuranderivater til anvendelse som anticancermidler
DK3256483T3 (da) Hidtil ukendt c-3-triterpenon med omvendte c-17-amidderivater som hiv-hæmmere patentkrav
LT3125894T (lt) Živ atvirkštinės transkriptazės inhibitorių provaistai
DK3196194T3 (da) Pyrimidinderivater, der er nyttige som selektive jak3- og/eller jak1-inhibitorer
DK3355933T3 (da) Adeninkonjugatforbindelser og deres anvendelse som vaccineadjuvanser
DK3319970T3 (da) Pyrido-oxazinonderivater som tnap-hæmmere
DK3372589T3 (da) Pyrimidinderivat
DK3277682T3 (da) 6-morpholinyl-2-pyrazolyl-9h-purinderivater og anvendelse heraf som pi3k- hæmmere
DK3233839T3 (da) Heterocyclylkoblede imidazopyridazinderivater som pi3k-beta-inhibitorer
DK3484875T3 (da) Pyrazolylaminobenzimidazolderivater som JAK-hæmmere